Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes

01 Apr 20264 min read0 viewsJournal Feed

GIST

This secondary analysis of a randomized clinical trial evaluates the effect of oral semaglutide on heart failure events, major adverse cardiovascular events, and safety among participants with or without heart failure at baseline.

Clinical Editorial

Summary

JAMA Internal Medicine published a clinical update in Research Highlights on 01 Apr 2026.

The item focuses on Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes.

Review the original article for the full source wording and details.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

Endocrine NewsRelated by Conditiondiabetesheart failure

Moving Forward: The Future of GLP-1 Therapies

Research Highlights • 11 Mar 2026

Endocrine NewsRelated by Conditiondiabetesheart failure

Moving Forward: The Future of GLP-1 Therapies

Research Highlights • 11 Mar 2026

Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies

Research Highlights • 21 May 2026

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial

Research Highlights • 13 May 2026

Med News TodayRelated by Conditiondiabetessemaglutide

New Ozempic pill may offer more affordable alternative to injectables

Research Highlights • 05 May 2026

Data-driven prioritization of high-risk individuals for weight loss interventions

Research Highlights • 30 Apr 2026

Feed Metadata

Source

JAMA Internal Medicine